News and Info

Welcome to the News and Information section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed of the latest news and activities of the organization. The information below includes press releases, announcements, media advisories, and links to news articles.

We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.


Latest News

August 20, 2024

Blinatumomab improves 3-year overall survival in B-ALL versus chemotherapy (study E1910)

August 17, 2024

Nivolumab’s role in esophageal cancer neoadjuvant therapy: Dr. Jennifer Eads (study EA2174)

August 14, 2024

The August 2024 News from ECOG-ACRIN blog is now available

August 1, 2024

Advocate Health Care and Aurora Health Care cancer clinics join the EAQ211 trial, which seeks to determine why young lymphoma survivors are at high risk for other health problems

July 24, 2024

Press Release: New England Journal of Medicine publishes practice-changing E1910 trial results

July 9, 2024

ECOG-ACRIN research advocate and prostate cancer survivor Brian Jones is profiled in Cancer Today

July 3, 2024

The July 2024 News from ECOG-ACRIN blog is now available

July 2, 2024

The Summer 2024 advocacy blog, Considering Clinical Trials, is now available

July 1, 2024

New Patient Video: Study chair Dr. Raquibul Hannan and advocate Glenn Sykes discuss the SOAR trial for patients with kidney cancer

June 18, 2024

Dr. Barbara Burtness and colleagues highlight progress in head and neck cancer MRD at ASCO, but caution that results remain preliminary (free registration is required to view this article)

June 14, 2024

E1910 trial leads to an FDA approval in B-cell acute lymphoblastic leukemia (B-ALL)

June 13, 2024

Nivolumab fails to benefit esophageal cancer treatment in the EA2174 trial: Dr. Jennifer Eads

June 13, 2024

Dr. Jennifer Eads on nivolumab plus neoadjuvant chemoradiation in esophageal/GEJ cancer (trial EA2174)

June 13, 2024

Personalizing chemotherapy for Black women in study EAZ171 (story by the Susan G. Komen organization)

June 13, 2024

EAZ171 trial suggests Black patients with breast cancer have lower risk of taxane-induced peripheral neuropathy with docetaxel than paclitaxel

June 13, 2024

Study EAZ171 suggests docetaxel is superior for neuropathy in Black patients with breast cancer

June 13, 2024

The June 2024 News from ECOG-ACRIN blog is now available

June 3, 2024

Press Release: ECOG-ACRIN completes first trial of Black patients with early-stage breast cancer

May 22, 2024

Press Release: TMIST breast cancer screening trial enrollment surpasses 100,000

May 16, 2024

CompassHER2 pCR trial to evaluate the HER2DX® score

 
ECOG-ACRIN Cancer Research Group